Articles by Aaron Lorenzo

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Oct. 31, 2003

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today)

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Oct. 31, 2003

By Aaron Lorenzo

No Comments

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Oct. 31, 2003

By Aaron Lorenzo

No Comments

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Oct. 31, 2003

By Aaron Lorenzo

No Comments

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today)

Guilford Gains U.S. Rights To Cardiovascular Product

Oct. 30, 2003

By Aaron Lorenzo

No Comments

Guilford Gains U.S. Rights To Cardiovascular Product

Oct. 30, 2003

By Aaron Lorenzo

No Comments

Avera In-Licenses From Novartis Anxiety, Depression Compound

Oct. 29, 2003

By Aaron Lorenzo

No Comments

Avera In-Licenses From Novartis Anxiety, Depression Compound

Oct. 29, 2003

By Aaron Lorenzo

No Comments

Remicade's Phase III Data Support Label Expansion In Spinal Arthritis

Oct. 28, 2003

By Aaron Lorenzo

No Comments

Remicade's Phase III Data Support Label Expansion In Spinal Arthritis

Oct. 28, 2003

By Aaron Lorenzo

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Articles by Aaron Lorenzo

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

Guilford Gains U.S. Rights To Cardiovascular Product

Guilford Gains U.S. Rights To Cardiovascular Product

Avera In-Licenses From Novartis Anxiety, Depression Compound

Avera In-Licenses From Novartis Anxiety, Depression Compound

Remicade's Phase III Data Support Label Expansion In Spinal Arthritis

Remicade's Phase III Data Support Label Expansion In Spinal Arthritis

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership